{"disease":{"id":"hospital-acquired-bacterial-pneumonia-ventilator-associated-bacterial-pneumonia","name":"hospital acquired bacterial pneumonia ventilator associated bacterial pneumonia"},"drugs":{"marketed":[{"drug_id":"zavicefta-ceftazidime-avibactam","indication_name":"Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible bacteria.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zavicefta, Ceftazidime-Avibactam","generic_name":"zavicefta-ceftazidime-avibactam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial cell wall synthesis","drug_class":"Cephalosporin antibiotic and beta-lactamase inhibitor combination","quality_score":55,"revenue":"638","mechanism":""},{"drug_id":"relebactam","indication_name":"Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Recarbrio","generic_name":"RELEBACTAM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Renal Dehydropeptidase Inhibitor [EPC]","quality_score":34,"revenue":null,"mechanism":"Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05204563","title":"Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":450,"lead_sponsor_name":"Evopoint Biosciences Inc.","has_results":true},{"nct_id":"NCT03583333","title":"Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":274,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT07326540","title":"Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":248,"lead_sponsor_name":"BioVersys SAS","has_results":false},{"nct_id":"NCT03894046","title":"Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":207,"lead_sponsor_name":"Entasis Therapeutics","has_results":true},{"nct_id":"NCT05905055","title":"P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Meiji Seika Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT04215991","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Shionogi","has_results":false},{"nct_id":"NCT01970371","title":"A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Achaogen, Inc.","has_results":true}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}